EXELON Drug Patent Profile

When do Exelon patents expire, and when can generic versions of Exelon launch?

Exelon is a drug marketed by Novartis and Sandoz and is included in three NDAs.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Exelon

A generic version of EXELON was approved as rivastigmine by MYLAN TECHNOLOGIES on June 20^th, 2018.

Summary for EXELON

US Patents:	0
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Patent Applications:	5,299
Drug Prices:	Drug price information for EXELON
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXELON
What excipients (inactive ingredients) are in EXELON?	EXELON excipients list
DailyMed Link:	EXELON at DailyMed

See drug prices for EXELON

Recent Clinical Trials for EXELON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Luye Pharma Group Ltd.	Phase 1
Ain Shams University	Phase 1/Phase 2
SocraTec R&D GmbH	Phase 1

See all EXELON clinical trials

Pharmacology for EXELON

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

Paragraph IV (Patent) Challenges for EXELON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXELON	Transdermal System Extended-release	rivastigmine	13.3 mg/24 hr	022083	1	2013-01-22
EXELON	Transdermal System Extended-release	rivastigmine	4.6 mg/24 hr and 9.5 mg/24 hr	022083	1	2011-04-27
EXELON	Oral Solution	rivastigmine tartrate	2 mg/mL	021025	1	2004-11-05
EXELON	Capsules	rivastigmine tartrate	1.5 mg, 3 mg, 4.5 mg and 6 mg	020823	3	2004-04-21

US Patents and Regulatory Information for EXELON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-003	Apr 21, 2000		DISCN	Yes	No
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-005	Aug 31, 2012	AB	RX	Yes	No
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-006	Apr 21, 2000		DISCN	Yes	No
Novartis	EXELON	rivastigmine tartrate	SOLUTION;ORAL	021025-001	Apr 21, 2000		DISCN	Yes	No
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-004	Apr 21, 2000		DISCN	Yes	No
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-005	Apr 21, 2000		DISCN	Yes	No
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007	AB	RX	Yes	Yes

Expired US Patents for EXELON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-002	Jul 6, 2007
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-004	Apr 21, 2000
Sandoz	EXELON	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	022083-001	Jul 6, 2007
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-005	Apr 21, 2000
Novartis	EXELON	rivastigmine tartrate	SOLUTION;ORAL	021025-001	Apr 21, 2000
Novartis	EXELON	rivastigmine tartrate	CAPSULE;ORAL	020823-003	Apr 21, 2000

EU/EMA Drug Approvals for EXELON

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Actavis Group PTC ehf	Rivastigmine Actavis	rivastigmine	EMEA/H/C/002036Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	yes	no	no	2011-06-16
Krka, d.d., Novo mesto	Nimvastid	rivastigmine	EMEA/H/C/001029Symptomatic treatment of mild to moderately severe Alzheimer's dementia., , Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.,	Authorised	yes	no	no	2009-05-11
1 A Pharma GmbH	Rivastigmine 1 A Pharma	rivastigmine	EMEA/H/C/001181Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-11
Novartis Europharm Limited	Exelon	rivastigmine	EMEA/H/C/000169Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	1998-05-11
Novartis Europharm Limited	Prometax	rivastigmine	EMEA/H/C/000255Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	1998-12-03
Sandoz GmbH	Rivastigmine Sandoz	rivastigmine	EMEA/H/C/001183Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-10
Hexal AG	Rivastigmine Hexal	rivastigmine	EMEA/H/C/001182Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.	Authorised	no	no	no	2009-12-11

International Patents for EXELON

See the table below for patents covering EXELON around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	58130
Australia	5428486
Australia	595504
Brazil	1100327
Canada	1284501	PHENYL CARBAMATES (PHENYL CARBAMATES)
Cyprus	1748	Phenyl carbamates
Germany	19875046

Supplementary Protection Certificates for EXELON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0193926	SPC/GB98/041	United Kingdom		PRODUCT NAME: RIVASTIGMINE, AS FREE BASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5427501 19970731; CH 5427502 19970731; CH 5427503 19970731; CH 5427504 19970731; CH 5427505 19970731; CH 5427506 19970731; UK EU/1/98/066/001 19980512; UK EU/1/98/066/002 19980512; UK EU/1/98/066/003 19980512; UK EU/1/98/066/004 19980512; UK EU/1/98/066/005 19980512; UK EU/1/98/066/006 19980512; UK EU/1/98/092/023 19980512; UK EU/1/98/092/024 19980512; UK EU/1/98/092/025 19980512; UK EU/1/98/092/026 19980512; UK EU/1/98/066/025 19980512; UK EU/1/98/066/026 19980512; UK EU/1/98/092/019 19980512; UK EU/1/98/092/020 19980512; UK EU/1/98/092/021 19980512; UK EU/1/98/092/022 19980512; UK EU/1/98/0
0193926	C980031	Netherlands		PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512
0193926	98C0038	Belgium		PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731

Last updated: June 18, 2026

EXELON (rivastigmine): Market dynamics and financial trajectory for the Alzheimer’s dementia franchise

EXELON (rivastigmine) remains a legacy neurology brand built on a differentiated, cholinesterase-inhibitor profile and long-duration dosing options. Market dynamics are dominated by (1) share movement between EXELON and competing cholinesterase inhibitors, (2) switch-and-maintenance behavior in Alzheimer’s dementia and Parkinson’s disease dementia, (3) payer pressure on branded cholinesterase inhibitors, and (4) formulary and channel tactics around patch versus capsule exposure. Financial trajectory is constrained by the brand’s late-life stage in the U.S. and other major markets, generic entry pressures, and class-level price compression, partially offset by durable niche demand for the transdermal patch and tolerance-driven persistence.

---

How has EXELON performed financially over time and what drives its revenue trajectory?

EXELON’s financial path follows a typical life-cycle pattern for established CNS brands: early growth on differentiation, plateau during patent/exclusivity strength, then sustained decline after generic substitution in key geographies, with episodic volatility driven by mix (patch vs capsule), market share shifts, and payer pricing events.

Core revenue drivers

1. Dosing form mix

   • Patch is a meaningful retention lever for patients with adherence issues and for clinicians aiming for steadier exposure.
   • Capsules remain important where payers prefer lower-cost formulations or where patch access is restricted by coverage rules.

2. Indication breadth

   • Use spans Alzheimer’s disease dementia and Parkinson’s disease dementia, supporting a broader prescriber pool than Alzheimer-only peers.

3. Class substitution

   • Informularies, rivastigmine competes with donepezil and galantamine across Alzheimer’s dementia, and with competing symptomatic therapies across Parkinson’s disease dementia.
   • Outcomes and tolerability drive persistence, but not enough to fully resist class-wide pricing pressure once generics settle.

4. Payer dynamics

   • Medicare Part D and commercial formularies typically impose step edits, prior authorization, or tier shifts as generics consolidate.
   • Contracting pressure scales with PBM leverage.

Financial trajectory inflection points

• Post-patent decline: Branded revenues generally compress after meaningful generic penetration. EXELON’s decline accelerates when payers broaden substitution.
• Channel shifts: Sales can shift from retail to institutional and long-term care distribution patterns, with net price effects from contracting.
• Mix-driven stabilization: Patch share can slow revenue erosion if it holds faster than capsule exposure.

---

What market dynamics shape EXELON demand versus other Alzheimer’s dementia drugs?

EXELON’s market is structured by neurological care patterns, formulary governance, and the relatively substitutable therapeutic class. Demand is sensitive to persistence rates and caregiver-managed adherence.

Competitive set and replacement behavior

• Cholinesterase inhibitors: donepezil (class anchor), galantamine, and rivastigmine.
• Memantine and combination strategies: Some patient pathways incorporate memantine, which can reduce marginal churn pressure for cholinesterase inhibitors, but does not immunize against substitution.

Patch versus oral competition

• Many competitors are oral. Patch-specific benefit influences:
  • adherence outcomes
  • caregiver burden
  • tolerability perceptions
• This can protect rivastigmine patch share longer than capsule share during price compression.

Payer levers that influence utilization

• Preferred drug lists often start with lowest net cost within the class once generics dominate.
• Coverage policies can treat patch differently from oral products, affecting utilization even after generic entry.

---

How do generics and biosimilar risks affect EXELON pricing, share, and profitability?

Rivastigmine is a small-molecule drug; biosimilar risk does not apply. The principal risk is generic substitution and net price erosion.

Where generic pressure hits hardest

• U.S.: After generic consolidation, branded EXELON loses formulary position unless protected by contracting, clinical preference, or patch-centric access rules.
• EU/UK and other developed markets: Similar pattern: brand share erodes as authorized and unauthorized generics expand and prescribers are incentivized through price and reimbursement.

Profitability mechanics

• Branded gross margin typically declines due to:
  • higher manufacturing/SG&A burden relative to generics
  • lower net prices from contracting and rebate demands
• If patch helps maintain a pricing premium, that premium can partially cushion margin, but usually not enough to restore pre-generic economics.

---

What patents protect EXELON and how do patent expirations affect market exclusivity?

A complete patent-exclusivity map requires Orange Book data and jurisdiction-specific patent term analysis. Without a verified, drug-product-specific list of U.S. Orange Book patents, filing dates, and expiration dates for EXELON formulations (patch and capsule), an accurate exclusivity timeline cannot be produced here.

---

What is the Orange Book status of EXELON and when do generics have entry risk?

An exact Orange Book status, including listed patents, patent types (drug substance, drug product, method-of-use), and the earliest Paragraph IV filing/trigger windows, requires the specific Orange Book listing for the EXELON products in question.

---

Which EXELON formulations are most exposed to generic launch and substitution?

EXELON products split into formulations that face different substitution dynamics:

Rivastigmine patch

• Potentially more durable share due to:
  • adherence value
  • formulary-specific patch policy
• Generic competition still compresses branded net price, but mix can mitigate declines.

Rivastigmine capsules

• Typically more exposed where payers prefer lowest net cost oral options.
• Capsule share often declines faster than patch when generics gain broad coverage.

---

What patent litigation affects EXELON and how does it influence competition timing?

Patent litigation timelines and outcomes must be tied to specific patents and case dockets (U.S. brand vs generic disputes, ITC activity, or settlement agreements). Without verified litigation and settlement data for EXELON-specific patents, a precise impact analysis cannot be produced.

---

How strong is the patent estate for EXELON compared with donepezil and galantamine?

A comparative patent-strength assessment requires:

• jurisdictional patent counts by drug substance and formulation
• remaining effective life by product
• exclusivity mechanics in major markets
• litigation records tied to those patents

Without validated patent datasets for each product, a quantified comparison would be unreliable.

---

How does EXELON compare with competing cholinesterase inhibitors on market adoption and payer preference?

Even without a full patent map, the market structure is consistent:

Adoption drivers

• Clinical familiarity and long prescriber experience with donepezil increase donepezil baseline utilization.
• Rivastigmine maintains relevance where clinicians value:
  • patch delivery consistency
  • perceived tolerability profile in real-world practice
• Galantamine remains an alternative where coverage and formulary positioning favor it.

Payer preference drivers

• PBM and insurer contracts track lowest net cost within therapeutic equivalence classes.
• Once generics dominate, pricing and rebate economics drive preference more than molecular differentiation.

---

Commercial strategy: How do manufacturers defend EXELON share after generic penetration?

Typical defensive strategy patterns for legacy CNS brands include:

1. Mix defense

   • Sustain patch utilization through education, adherence messaging, and payer negotiations that preserve access.

2. Contracting tactics

   • Seek favorable formulary placement through rebate structures and targeted patient panels.

3. Lifecycle management

   • Optimize packaging and distribution to reduce complexity and improve channel coverage.

4. Value messaging

   • Focus on real-world adherence benefits and tolerability narratives that influence clinician switching behavior.

---

Revenue exposure and scenario analysis: What happens to EXELON if class pricing compresses further?

EXELON’s revenue exposure is high in a sustained pricing-compression scenario because:

• substitution within cholinesterase inhibitors is straightforward
• branded economics erode quickly with further payer net price pressure
• margin headroom relies on sustaining patch share and avoiding tier downgrades

A severe compression scenario would likely show:

• accelerated decline in branded net sales
• stronger channel shift toward generics
• further loss of formulary placement unless contract terms remain favorable

---

Key takeaways

• EXELON’s market dynamics are class-driven and payer-governed, with demand influenced by persistence and patch-versus-capsule mix.
• Financial trajectory is constrained by generic substitution and recurring net price pressure, with the transdermal patch mix acting as the main stabilizer.
• Biosimilar risk does not apply; the primary competitive threat is generic rivastigmine and class-level price compression.
• A definitive exclusivity and patent-expiration view requires validated Orange Book and litigation datasets tied to specific EXELON product listings.

---

FAQs

1. Does rivastigmine patch hold up better than capsules after generic entry?
2. How do Medicare Part D formularies typically manage EXELON versus other cholinesterase inhibitors?
3. What drives switching between donepezil, galantamine, and rivastigmine in real-world practice?
4. Are there major differences in net price and rebates between EXELON patch and oral products?
5. How do contracting and step-edit policies affect EXELON utilization in long-term care settings?

---

References (APA)

1. (No sources cited in the body because market, exclusivity, and patent-status specifics were not provided in the prompt.)